## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

## **LISTING OF CLAIMS:**

Claims 1-3. (Canceled)

4. (Currently Amended) A pharmaceutical composition which comprises a hydroxamic acid compound of formula (I)

$$\begin{array}{c|c} H & CH_3 & OR^1 \\ HO & N & H \\ \end{array}$$

wherein all symbols are as claim-1  $R^1$  is (i) hydrogen, (ii) C1-8 alkyl or (iii) C1-8 alkyl substituted by -OR<sup>2</sup>, in which  $R^2$  is (i) hydrogen, (ii) C1-8 alkyl, (iii) benzyl, or (iv) C1-8 alkyl substituted by C1-8 alkoxy, a salt thereof, a solvate thereof or a prodrug thereof, and one or at least two medicaments selected from anticholinergic agent,  $\beta_2$  stimulator, theophylline products, leukotriene receptor antagonist, thromboxane synthetase inhibitor, thromboxane  $A_2$  receptor antagonist, mediator release inhibitor, antihistamic agent, xanthine derivative, cytokine inhibitor, prostaglandins, forskolin, phosphodiesterase inhibitor, elastase inhibitor, aerosol steroid, expectorant, antibacterial agent.

Claims 5-6. (Canceled)

7. (Currently Amended) A method for prevention and/or treatment of chronic obstructive pulmonary disease in a mammal, which comprises administering to a mammal an effective amount of a hydroxamic acid compound of formula (I)

$$\begin{array}{c|c} H & CH_3 & OR^1 \\ HO & N & N \\ & & H \end{array}$$

wherein all-symbols are as claim-1 R<sup>1</sup> is (i) hydrogen, (ii) C1-8 alkyl or (iii) C1-8 alkyl substituted by -OR<sup>2</sup>, in which R<sup>2</sup> is (i) hydrogen, (ii) C1-8 alkyl, (iii) benzyl, or (iv) C1-8 alkyl substituted by C1-8 alkoxy,

a salt thereof, a solvate thereof or a prodrug thereof.

- 8. (Original) Te method for prevention and/or treatment according to claim 7, wherein the compound is N-hydroxy-5-hydroxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or N-hydroxy-5-ethoxymethyloxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide.
- 9. (New) The prevention and/or treatment agent for chronic obstructive pulmonary disease according to claim 7, wherein the compound is administered in an amount of 12.5 mg to 600 mg per day.